United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report & Forecast 2021-2027

1 Introduction to Research & Analysis Reports
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year

2 United States Benign Prostatic Hyperplasia (BPH) Drugs Overall Market Size
2.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size: 2021 VS 2027
2.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales: 2016-2027

3 Company Landscape
3.1 Top Benign Prostatic Hyperplasia (BPH) Drugs Players in United States Market
3.2 Top United States Benign Prostatic Hyperplasia (BPH) Drugs Companies Ranked by Revenue
3.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Companies
3.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Companies
3.5 United States Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Benign Prostatic Hyperplasia (BPH) Drugs Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Players in United States Market
3.8.1 List of Tier 1 Benign Prostatic Hyperplasia (BPH) Drugs Companies in United States
3.8.2 List of Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Companies in United States

4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size Markets, 2021 & 2027
4.1.2 Alpha-Blocker
4.1.3 Phosphodiesterase Type-5 Inhibitors
4.1.4 Others
4.2 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue & Forecasts
4.2.1 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2021
4.2.2 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2022-2027
4.2.3 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027
4.3 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales & Forecasts
4.3.1 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2016-2021
4.3.2 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2022-2027
4.3.3 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027
4.4 By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Price (Manufacturers Selling Prices), 2016-2027

5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size, 2021 & 2027
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue & Forecasts
5.2.1 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2021
5.2.2 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2022-2027
5.2.3 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027
5.3 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales & Forecasts
5.3.1 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2016-2021
5.3.2 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2022-2027
5.3.3 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027
5.4 By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Price (Manufacturers Selling Prices), 2016-2027

6 Manufacturers & Brands Profiles
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.1.5 Eli Lilly Recent Developments
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.2.5 GlaxoSmithKline Recent Developments
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.3.5 Astellas Pharma Recent Developments
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.4.5 Sanofi Recent Developments
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.5.5 Pfizer Recent Developments
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.6.5 Abbott Recent Developments
6.7 Allergan
6.7.1 Allergan Corporation Information
6.7.2 Allergan Overview
6.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.7.5 Allergan Recent Developments
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.8.5 TEVA Recent Developments
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.9.5 Mylan Recent Developments
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.10.5 Novartis Recent Developments
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in United States Market (2016-2021)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Description
6.11.5 Merck Recent Developments

7 United States Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Analysis
7.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, 2016-2027
7.2 Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity of Key Manufacturers in United States Market

8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints

9 Benign Prostatic Hyperplasia (BPH) Drugs Supply Chain Analysis
9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Value Chain
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Upstream Market
9.3 Benign Prostatic Hyperplasia (BPH) Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors and Sales Agents in United States Market

10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer

List of Tables
Table 1. Key Players of Benign Prostatic Hyperplasia (BPH) Drugs in United States Market
Table 2. Top Benign Prostatic Hyperplasia (BPH) Drugs Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Companies, 2016-2021
Table 5. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Companies, (M Units), 2016-2021
Table 6. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2016-2021) & (US$/Unit)
Table 8. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 9. List of Tier 1 Benign Prostatic Hyperplasia (BPH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Alpha-Blocker
Table 12. Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Table 13. By Type – United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2016-2021
Table 17. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2022-2027
Table 18. By Application – United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2016-2021
Table 22. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2022-2027
Table 23. Eli Lilly Corporation Information
Table 24. Eli Lilly Description and Major Businesses
Table 25. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 26. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 27. Eli Lilly Recent Developments
Table 28. GlaxoSmithKline Corporation Information
Table 29. GlaxoSmithKline Description and Major Businesses
Table 30. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 31. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 32. GlaxoSmithKline Recent Developments
Table 33. Astellas Pharma Corporation Information
Table 34. Astellas Pharma Description and Major Businesses
Table 35. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 36. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 37. Astellas Pharma Recent Developments
Table 38. Sanofi Corporation Information
Table 39. Sanofi Description and Major Businesses
Table 40. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 41. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 42. Sanofi Recent Developments
Table 43. Pfizer Corporation Information
Table 44. Pfizer Description and Major Businesses
Table 45. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 46. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 47. Pfizer Recent Developments
Table 48. Abbott Corporation Information
Table 49. Abbott Description and Major Businesses
Table 50. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 51. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 52. Abbott Recent Developments
Table 53. Allergan Corporation Information
Table 54. Allergan Description and Major Businesses
Table 55. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 56. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 57. Allergan Recent Developments
Table 58. TEVA Corporation Information
Table 59. TEVA Description and Major Businesses
Table 60. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 61. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 62. TEVA Recent Developments
Table 63. Mylan Corporation Information
Table 64. Mylan Description and Major Businesses
Table 65. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 66. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 67. Mylan Recent Developments
Table 68. Novartis Corporation Information
Table 69. Novartis Description and Major Businesses
Table 70. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 71. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 72. Novartis Recent Developments
Table 73. Merck Corporation Information
Table 74. Merck Description and Major Businesses
Table 75. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 76. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 77. Merck Recent Developments
Table 78. Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity (M Units) of Key Manufacturers in United States Market, 2019-2021 (M Units)
Table 79. United States Benign Prostatic Hyperplasia (BPH) Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 80. Benign Prostatic Hyperplasia (BPH) Drugs Market Opportunities & Trends in United States Market
Table 81. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers in United States Market
Table 82. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints in United States Market
Table 83. Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials
Table 84. Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials Suppliers in United States Market
Table 85. Typical Benign Prostatic Hyperplasia (BPH) Drugs Downstream
Table 86. Benign Prostatic Hyperplasia (BPH) Drugs Downstream Clients in United States Market
Table 87. Benign Prostatic Hyperplasia (BPH) Drugs Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
Figure 3. Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
Figure 4. United States Benign Prostatic Hyperplasia (BPH) Drugs Market Overview: 2020
Figure 5. United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Benign Prostatic Hyperplasia (BPH) Drugs Sales in United States Market: 2016-2027 (M Units)
Figure 8. The Top 3 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020
Figure 9. Alpha-Blocker Product Picture
Figure 10. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 11. Others Product Picture
Figure 12. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027
Figure 13. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027
Figure 14. By Type - United States Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit), 2016-2027
Figure 15. Hospitals
Figure 16. Drugstores
Figure 17. Others
Figure 18. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027
Figure 19. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027
Figure 20. By Application - United States Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit), 2016-2027
Figure 21. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 22. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Merck Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. United States Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity (M Units), 2016-2027
Figure 33. Benign Prostatic Hyperplasia (BPH) Drugs Industry Value Chain
Figure 34. Marketing Channels

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.